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Abstract
A cohort of 154 French Hajj pilgrims participating in the 2012 Hajj
were systematically sampled with nasal swabs prior to returning to
France, and screened for the novel HCoV-EMC coronavirus by
two real-time RT-PCR assays. Despite a high rate of respiratory
symptoms (83.4%), including 41.0% influenza-like illness, no case of
HCoV-EMC infection was detected. Despite the fact that zoonotic
transmission was suspected in the first few cases, a recent family
cluster in the Kingdom of Saudi Arabia suggests that the virus
might show at least limited spread from person to person, which
justifies continuing epidemiological surveillance.
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To date, nine human cases of severe respiratory infections
caused by a previously unknown coronavirus called HCoV-
EMC (for Erasmus Medical Centre) have been documented
since June 2012 [1–5]. Five cases, three of which were fatal,
occurred in Saudi Arabian citizens. Two cases occurred in
Qatari citizens, including one who travelled to Saudi Arabia
2 weeks before the onset of the disease. Two fatal cases
occurred in Jordan. So far, only the three most recently
confirmed cases in Saudi Arabia have been epidemiologically
linked—they are from the same family, living in the same
household. No secondary cases were observed in the hospital
among doctors and nurses caring for the patients, which
suggests that the disease did not spread readily. A history of
animal contact with camels, sheep and bats has been
documented.
These nine cases of HCoV-EMC infection may represent
occasional transmission of the virus from animals to humans,
manifesting as severe infections with no subsequent human-to-
human transmission. Despite the apparently low transmissibil-
ity of HCoV-EMC at this stage, it may also be the beginning of
another SARS-like pandemic, in which there will be increasing
animal-to-human and subsequent human-to-human transmis-
sion [6]. Alternatively, these nine documented cases may just
represent the tip of an iceberg, with a majority of cases
remaining undetected because of mild or asymptomatic forms
of infection [6]. From a public health point of view, serious
attention should be paid to the surveillance of influenza-like
illnesses in the Middle East region, as the extremely crowded
Hajj (pilgrimage to Makkah) season has just ended [7].
This article reports a prospective cohort study carried in
Saudi Arabia in October–November 2012. Participants in the
survey were Hajj pilgrims travelling with one specialized travel
agency in Marseille. Pilgrims older than 18 years were included
on a voluntary basis, and participants were asked to sign a
written consent form. Follow-up was conducted by a French
Muslim Arabic-speaking medical doctor during the journey
period, who systematically documented travel-associated dis-
eases (medical consultation, hospitalization, fever, cough, and
other respiratory symptoms). Nasal swabs were obtained
from all of the study participants: (i) just before leaving France
to travel to Saudi Arabia; and (ii) just before returning from
Saudi Arabia to France, regardless of their medical condition.
Additional samples were obtained during the stay in Saudi
Arabia from symptomatic patients, in a number of cases.
Samples were placed in viral transport medium at the point of
collection, kept at room temperature, and transported to the
Marseille laboratory for storage at 80°C. Total nucleic acids
were purified from a 200-lL volume of sample spiked with
MS2 + T4 bacteriophage as internal control [8], by use of the
BIOROBOT EZ1 XL with the Virus Mini kit v2.0 (both from
Qiagen, Courtaboeuf, France). Each sample was tested inde-
pendently with the two systems developed by Corman et al.
[9] in a 25-lL reaction containing 5 lL of RNA, 12.5 lL of 2X
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buffer (iScriptTM One-Step RT-PCR Kit for Probes (BioRad,
Marnes-la-Coquette, France)), 1 lL of reverse transcriptase/
Taq, 400 nM each primer, and 160 nM probe. The cycling
profile (50°C for 10 min, followed by 95°C for 5 min, and then
45 cycles of 95°C for 15 s and 60°C for 30 s) was obtained on
BioRad CFX 96 cyclers. The limit of detection was tested at 90
and 820 genome equivalents per reaction for the ORF1b and
the UpE system, respectively. Ethical approval was obtained
from the Saudi authorities.
A total of 169 pilgrims were included on departure from
France. The mean age was 59.3 years (range: 21–83 years),
and the male/female ratio was 0.6. Most of them were born in
North Africa (90.4%) and had settled in France >20 years
before (85.8%). A proportion of 57.5% declared suffering from
a chronic disease, including diabetes (27.5%), hypertension
(26.3%), chronic respiratory infection (7.8%), and chronic
cardiac disease (7.2%). A proportion of 45.6% declared having
received influenza vaccination in 2012, before participating in
the Hajj. Clinical data were available for 157 individuals
(92.9%), of whom 90.4% suffered from respiratory symptoms
during their stay in Saudi Arabia, including cough (83.4%) and
sore throat (79.7%); 41.0% met the criteria for influenza-like
illness (ILI) as defined by the association of cough, sore throat,
and fever. One patient only was hospitalized (ILI + diarrhoea).
A total of 70 (41.4%) pilgrims who suffered from respiratory
symptoms had a nasal swab taken while they had symptoms.
One hundred and fifty-four pilgrims (91.1%) had a systematic
nasal swab taken during the 3 days before returning to France.
All PCRs were negative for HCoV-EMC, with the two RT-PCR
assays. These patients were tested with the two initially
reported RT-PCR systems (ORF1b and UpE).
The detection limit of our adapted tests is different from
that reported by Corman et al. [9], probably because of
technical differences (equipment and RT-PCR kit). However,
the sensitivity of the combined tests is satisfactory.
The purpose of our work was not to investigate patients
meeting the case definition for suspicion of HCoV-EMC
infection [10], but to investigate the potential circulation of
HCoV-EMC in Hajj pilgrims independently of the occurrence
of respiratory symptoms. Clinical data from the 2012 cohort
show higher rates of cough (83.4% vs. 48.5%), sore throat
(79.9% vs. 36.1%) and ILI (41.0% vs. 8.0%) than in a previous
study conducted on French pilgrims during the 2009 Hajj [11].
This may be attributable to better follow-up of pilgrims in
2012, which was probably greatly helped by the presence of a
medical doctor together with pilgrims during the Hajj; the
2009 survey was conducted by telephone interview after
pilgrims had returned to France. This may also account for an
actual higher rate of respiratory infections in 2012. Seasonal
influenza vaccine is recommended for Hajj pilgrims by the
French Ministry of Health [12]. The lower influenza vaccination
rate among pilgrims of the 2012 cohort, recruited at a travel
agency (40.3%), than among pilgrims of the 2009 cohort,
recruited when they were receiving pre-travel advice at our
clinic (97.4%) [11], may also possibly account for the higher
rate of ILI in 2012 than in 2009. Our results are based on
relatively small numbers of individuals, and are therefore not
representative of all pilgrims participating in the Hajj. How-
ever, the absence of HCoV-EMC among French pilgrims
despite a very high attack rate of cough episodes suggests that
the virus did not play a major role in the epidemiology of Hajj-
associated respiratory infections during 2012.
At present, the very few available data on the behaviour of
HCoV-EMC do not support human-to-human transmission of
the virus, and suggest that zoonotic transmission is likely.
However, the recent family cluster in the Kindom of Saudi
Arabia suggests that the virus might show at least limited
spread from person to person, which justifies continuing
epidemiological surveillance. Further investigations are being
conducted to identify other pathogens among the 2012 French
pilgrim cohort.
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